470 related articles for article (PubMed ID: 8423216)
1. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin JA; Matsuo K; Karmakar A; Chen DL; Tang SH; Koeffler HP
J Clin Invest; 1993 Jan; 91(1):179-84. PubMed ID: 8423216
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations in all stages of thyroid carcinomas.
Zou M; Shi Y; Farid NR
J Clin Endocrinol Metab; 1993 Oct; 77(4):1054-8. PubMed ID: 8408453
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
Jossart GH; Epstein HD; Shaver JK; Weier HU; Greulich KM; Tezelman S; Grossman RF; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1996 Oct; 81(10):3498-504. PubMed ID: 8855792
[TBL] [Abstract][Full Text] [Related]
4. Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours.
Wright PA; Lemoine NR; Goretzki PE; Wyllie FS; Bond J; Hughes C; Röher HD; Williams ED; Wynford-Thomas D
Oncogene; 1991 Sep; 6(9):1693-7. PubMed ID: 1923534
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations in thyroid tumor progression: association with p53 gene mutations.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Jpn J Cancer Res; 1993 May; 84(5):526-31. PubMed ID: 8100564
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.
Nakamura T; Yana I; Kobayashi T; Shin E; Karakawa K; Fujita S; Miya A; Mori T; Nishisho I; Takai S
Jpn J Cancer Res; 1992 Dec; 83(12):1293-8. PubMed ID: 1483945
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
9. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
10. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms.
Zeki K; Spambalg D; Sharifi N; Gonsky R; Fagin JA
J Clin Endocrinol Metab; 1994 Nov; 79(5):1317-21. PubMed ID: 7962323
[TBL] [Abstract][Full Text] [Related]
11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
12. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland.
Ito T; Seyama T; Mizuno T; Tsuyama N; Hayashi T; Hayashi Y; Dohi K; Nakamura N; Akiyama M
Cancer Res; 1992 Mar; 52(5):1369-71. PubMed ID: 1737400
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutation in two out of fifty-six thyroid tumours.
Salvatore D; Celetti A; Fabien N; Paulin C; Martelli ML; Battaglia C; Califano D; Monaco C; Viglietto G; Santoro M; Fusco A
Eur J Endocrinol; 1996 Feb; 134(2):177-83. PubMed ID: 8630516
[TBL] [Abstract][Full Text] [Related]
14. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
Donghi R; Longoni A; Pilotti S; Michieli P; Della Porta G; Pierotti MA
J Clin Invest; 1993 Apr; 91(4):1753-60. PubMed ID: 8473515
[TBL] [Abstract][Full Text] [Related]
15. [Unique association of p53 mutations with undifferentiated carcinoma of the thyroid].
Ito T; Seyama T; Hayashi Y; Dohi K; Akiyama M
Nihon Rinsho; 1994 Apr; 52(4):1069-74. PubMed ID: 8196165
[TBL] [Abstract][Full Text] [Related]
16. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma.
Boltze C; Roessner A; Landt O; Szibor R; Peters B; Schneider-Stock R
Int J Oncol; 2002 Nov; 21(5):1151-4. PubMed ID: 12370767
[TBL] [Abstract][Full Text] [Related]
17. Lack of p16/CDKN2 alterations in thyroid carcinomas.
Yane K; Konishi N; Kitahori Y; Naito H; Okaichi K; Ohnishi T; Miyahara H; Matsunaga T; Hiasa Y
Cancer Lett; 1996 Mar; 101(1):85-92. PubMed ID: 8625287
[TBL] [Abstract][Full Text] [Related]
18. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumours without radiation history.
Smida J; Zitzelsberger H; Kellerer AM; Lehmann L; Minkus G; Negele T; Spelsberg F; Hieber L; Demidchik EP; Lengfelder E; Bauchinger M
Int J Cancer; 1997 Dec; 73(6):802-7. PubMed ID: 9399655
[TBL] [Abstract][Full Text] [Related]
20. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas.
Dobashi Y; Sugimura H; Sakamoto A; Mernyei M; Mori M; Oyama T; Machinami R
Diagn Mol Pathol; 1994 Mar; 3(1):9-14. PubMed ID: 8162258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
